Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz; Linda M Henricks; Steven M Offer; Julia Barbarino; Jan H M Schellens; Jesse J. Swen; Teri E Klein; Howard L McLeod; Kelly E Caudle; Robert B Diasio; Matthias Schwab

doi:10.1002/cpt.911

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz, Linda M Henricks, Steven M Offer, Julia Barbarino, Jan H M Schellens, Jesse J. Swen, Teri E Klein, Howard L McLeod, Kelly E Caudle, Robert B Diasio, Matthias Schwab

University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
Netherlands Cancer Institute
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
DeBartolo Family Personalized Medicine Institute and the Department of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota, USA.
Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

Original language	English
Pages (from-to)	210-216
Number of pages	7
Journal	Clinical Pharmacology and Therapeutics
Volume	103
Issue number	2
Early online date	20 Nov 2017
DOIs	https://doi.org/10.1002/cpt.911
Publication status	Published - 9 Jan 2018

Access to Document

10.1002/cpt.911

amstutzFinal published version, 142 KB

Cite this

Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., & Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 103(2), 210-216. https://doi.org/10.1002/cpt.911

@article{73083a54f6e14a58a8794713e2719587,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update",

abstract = "The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC{\textregistered}) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).",

author = "Ursula Amstutz and Henricks, {Linda M} and Offer, {Steven M} and Julia Barbarino and Schellens, {Jan H M} and Swen, {Jesse J.} and Klein, {Teri E} and McLeod, {Howard L} and Caudle, {Kelly E} and Diasio, {Robert B} and Matthias Schwab",

note = "{\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics.",

year = "2018",

month = jan,

day = "9",

doi = "10.1002/cpt.911",

language = "English",

volume = "103",

pages = "210--216",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "2",

}

Amstutz, U, Henricks, LM, Offer, SM, Barbarino, J, Schellens, JHM, Swen, JJ, Klein, TE, McLeod, HL, Caudle, KE, Diasio, RB & Schwab, M 2018, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update', Clinical Pharmacology and Therapeutics, vol. 103, no. 2, pp. 210-216. https://doi.org/10.1002/cpt.911

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. / Amstutz, Ursula; Henricks, Linda M; Offer, Steven M et al.
In: Clinical Pharmacology and Therapeutics, Vol. 103, No. 2, 09.01.2018, p. 210-216.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

T2 - 2017 Update

AU - Amstutz, Ursula

AU - Henricks, Linda M

AU - Offer, Steven M

AU - Barbarino, Julia

AU - Schellens, Jan H M

AU - Swen, Jesse J.

AU - Klein, Teri E

AU - McLeod, Howard L

AU - Caudle, Kelly E

AU - Diasio, Robert B

AU - Schwab, Matthias

PY - 2018/1/9

Y1 - 2018/1/9

N2 - The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

AB - The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

U2 - 10.1002/cpt.911

DO - 10.1002/cpt.911

M3 - Article

C2 - 29152729

SN - 0009-9236

VL - 103

SP - 210

EP - 216

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 2

ER -

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Abstract

Access to Document

Fingerprint

Cite this